Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

17.22 USD +0.24 (+1.41%)
Streaming Delayed Price Updated: 4:01 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,203,356
Open 17.13
Bid (Size) 16.50 (1)
Ask (Size) 17.35 (5)
Prev. Close 16.98
Today's Range 16.73 - 17.29
52wk Range 13.63 - 25.06
Shares Outstanding 171,402,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January... 
From PR Newswire
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served... 
From PR Newswire

Performance

YTD
-2.49%
-2.49%
1 Month
-7.67%
-7.67%
3 Month
+2.07%
+2.07%
6 Month
-29.94%
-29.94%
1 Year
-23.19%
-23.19%

More News

Read More
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
From PR Newswire
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colore
From PR Newswire
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm
From GlobeNewswire News Releases
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
From PR Newswire
First Week of NKTR March 19th Options Trading
Tags Stocks
From Market News Video
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From PR Newswire
How The Pieces Add Up: FBT Targets $202
Tags ETFs
From ETF Channel
February 26th Options Now Available For Nektar Therapeutics (NKTR)
Tags Stocks
From Market News Video
February 2021 Options Now Available For Nektar Therapeutics (NKTR)
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.